The 2018 Chinese Tumor Marker Academic Conference and 12th Young Scientists Forum concluded in Zhengzhou on September 16. The historical notice described approximately 1,000 attendees and more than 150 experts and industry leaders discussing research, translation and clinical practice.
The notice reported that Lifeint general manager Chen Maoli attended an exosome technology expert committee meeting on September 15 and was appointed a committee member. Participants discussed platelet- and EV-related liquid biopsy research.
Lifeint exchanged views with researchers on basic EV research and diagnostic translation. Technical director Ye Guodong also discussed challenges and possible directions in early cancer detection.
The notice described collaborations with research institutions and workflows for EV collection, isolation, preparation, characterization and functional validation, along with related publications.
The historical notice described Lifeint as a high-tech enterprise and discussed its platelet RNA sequencing and machine-learning research for early cancer detection. The notice does not itself establish clinical performance.
The team described the meeting as an opportunity to connect laboratory research, academic exchange and future clinical research.
Lifeint provides EV research and application services from sample preparation, isolation and characterization to omics, functional studies, modification and scale-up. It jointly established a biomedical technology centre with Xiamen University School of Pharmaceutical Sciences, built process-development laboratories to GMP standards, and contributed to an EV expert consensus. Its service records cover more than 300 plant species.
Scan to contact us on WeCom
